HER3 drugs for Non-Small Cell Lung Cancer

7 tracked HER3 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the HER3 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.

3 Phase 33 Phase 1/21 preclinical / unstaged

Head-to-head evidence: AK138D1 vs Nezutatug · AK138D1 vs Patritumab Deruxtecan · Beruzatatug pelitecan vs Nezutatug · Beruzatatug pelitecan vs Patritumab Deruxtecan · DB-1310 vs Nezutatug · DB-1310 vs Patritumab Deruxtecan

The roster

← all HER3 drugs